We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

3 stocks you can buy with dividends yielding more than 5%

Royston Wild reveals a cluster of huge yielders with dynamite investment potential.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Medicines giant GlaxoSmithKline (LSE: GSK) may not have raised the dividend in recent years — and isn’t expected to do so any time soon — but the stock still remains one of the FTSE 100’s most attractive dividend bets, certainly in my opinion.

GlaxoSmithKline has elected to keep the dividend locked at 80p per share through to the end of 2017, reflecting the hard work to transform its product pipeline via huge organic investment and nifty acquisitions. And the City expects the pharma giant to make good on this promise, meaning GlaxoSmithKline boasts a yield of 5.2% for the period.

Should you buy Barratt Redrow shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

Dividend coverage may not be the best, with readings of 1.3 times and 1.4 times falling below the safety benchmark of 2 times.

But predicted earnings rises of 33% and 10% in 2016 and 2017 respectively — snapping four successive annual slips, if realised — illustrate the hugely-improved bottom-line outlook created by GlaxoSmithKline’s revamped R&D operations and vast global reach. And I expect these factors to drive dividends skywards again beyond next year.

Build a fortune

The UK’s forthcoming battle against the economic implications of Brexit is expected to put the stellar earnings record of housebuilders under pressure in the months ahead.

Barratt Developments (LSE: BDEV), for one, is expected to post a rare 7% earnings slip in the period to June 2017 as home price growth moderates and construction costs rise.

But the number crunchers still expect Barratt Developments to remain a big-paying income stock, a dividend of 34.5p per share in the period currently predicted and resulting in a vast yield of 7.5%.

And while dividend coverage at Barratt Developments stands at just 1.5 times for fiscal 2017, the construction giant’s brilliant cash-generative qualities — net cash stormed to £592m in June from £186.5m a year earlier — is expected to keep shareholder rewards on an upward keel.

The long-term outlook for the housing market remains in very rude health, irrespective of any economic gyrations in 2017 as Britain’s embedded housing crunch keeps home values from collapsing through the floor. Meanwhile, ultra-supportive lending conditions and the government’s Help To Buy scheme should underpin homebuyer appetite.

Consequently I reckon the dividend outlook at Barratt Developments remains very attractive.

Phone favourite

I expect a strong sales bounceback in Europe, allied with soaring data demand in developing regions, to keep yields at Vodafone Group (LSE: VOD) sailing above the big-cap average of 3.5% long into the future.

While its £19bn Project Spring organic investment programme may be over, Vodafone’s operations are still massively cost-intensive, of course. And as well as forking out a fortune to keep its customers connected, the telecoms titan is also facing a huge bill as investment in 5G technology steadily rises.

As such, Vodafone is expected to pay a dividend of 12.5p per share in the period to March 2017 before trimming it back to 12.3p in the following period. Still, these figures yield a terrific 6.2% and 6.1%.

And although these figures soar above predicted earnings of 5.9p for this year and 7.3p for 2018, Vodafone has the cash might to finance bumper shareholder rewards, helped by the potential for further divestments.

On top of this, the prospect of electric earnings advances in the years ahead should  bolster investor confidence in current forcecasts — rises of 16% and 24% for fiscal 2017 and 2018 alone. I believe Vodafone should remain a favourite for income seekers for years to come.

Royston Wild has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

many happy international football fans watching tv
Investing Articles

3 cheap FTSE 250 stocks to consider buying before the 2026 World Cup kicks off

With the World Cup less than a week away, our writer highlights a trio of UK stocks to consider buying.…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

I’m aggressively buying this S&P 500 growth stock for my ISA while it’s down 40%

This S&P 500 tech stock is well off its highs at the moment. But it may not be at depressed…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

What on earth’s happening to the Barclays share price?

The Barclays share price has been jumping around of late and is up 11% in the past month. Ken Hall…

Read more »

A colourful firework display
Investing Articles

See what £12,000 in explosive JD Sports shares 1 month ago is worth today

After years of doom and gloom, JD sport shares are finally putting on a show. Harvey Jones examines how long…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

The BP share price is on a knife edge – so where does it go next?

Harvey Jones exams why the BP share price has been surprisingly jumpy, even as the oil price spikes. Should investors…

Read more »

Wall Street sign in New York City
Investing Articles

Is the FTSE 100 at risk from an overheated US stock market?

Christopher Ruane explains why the UK market could suffer if its bigger US cousin sinks -- and why he's still…

Read more »

Young black female footballer training on stadium pitch
Investing Articles

£1,000 buys 358 shares in this red-hot FTSE 250 stock that’s tipped to keep rising

Applied Nutrition is Edward Sheldon’s favourite FTSE 250 stock right now. Offering growth at a reasonable price, he believes it’s…

Read more »

Three generation family are playing football together in a field. There are two boys, their father and their grandfather.
Investing Articles

How much would you need to put in an ISA each week to try and retire a couple of years early?

Ever dreamt of retiring even a couple of years earlier than planned? An ISA could help make that a financially…

Read more »